BR112017004746A2 - métodos para preparação de virossomas adjuvados, para otimizar a proporção adjuvante/antígeno de uma vacina à base de virossoma e para imunizar um indivíduo contra uma doença, virossoma adjuvado, composição farmacêutica, e, composição imunogênica. - Google Patents

métodos para preparação de virossomas adjuvados, para otimizar a proporção adjuvante/antígeno de uma vacina à base de virossoma e para imunizar um indivíduo contra uma doença, virossoma adjuvado, composição farmacêutica, e, composição imunogênica.

Info

Publication number
BR112017004746A2
BR112017004746A2 BR112017004746A BR112017004746A BR112017004746A2 BR 112017004746 A2 BR112017004746 A2 BR 112017004746A2 BR 112017004746 A BR112017004746 A BR 112017004746A BR 112017004746 A BR112017004746 A BR 112017004746A BR 112017004746 A2 BR112017004746 A2 BR 112017004746A2
Authority
BR
Brazil
Prior art keywords
virosome
adjuvant
adjuvanted
virosomes
preparing
Prior art date
Application number
BR112017004746A
Other languages
English (en)
Other versions
BR112017004746B1 (pt
Inventor
Johannes Henrikus Stegmann Antonius
Claudia Maureen Soei-Ken Tjon Joan
Original Assignee
Bestewil Holding Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bestewil Holding Bv filed Critical Bestewil Holding Bv
Publication of BR112017004746A2 publication Critical patent/BR112017004746A2/pt
Publication of BR112017004746B1 publication Critical patent/BR112017004746B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18523—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

a invenção refere-se com os campos da imunologia e vacinologia. é provido um método para a preparação de virossomas adjuvante, compreendendo os etapas de: (i) prover uma composição aquosa de virossomas sem adjuvante compreendendo uma proteína de fusão de membrana; (ii) dissolver um adjuvante anfifílico em um solvente não aquoso farmaceuticamente aceitável que pode formar uma mistura homogénea com água; e (iii) diluir a referida solução adjuvante na referida composição aquosa de virossomas para induzir a inserção de adjuvante no folíolo externo da membrana virossômica enquanto se preserva a atividade de fusão da membrana dos virossomas. são também providos virossomas adjuvados que podem ser obtidos pelo referido método, e vacinas compreendendo os virossomas.
BR112017004746-2A 2014-09-12 2014-09-12 Métodos para preparação de virossomas adjuvados e para otimizar a proporção adjuvante/antígeno de uma vacina à base de virossoma, virossoma adjuvado, composição farmacêutica, e, composição imunogênica BR112017004746B1 (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/NL2014/050627 WO2016039619A1 (en) 2014-09-12 2014-09-12 Methods for providing adjuvanted virosomes and adjuvanted virosomes obtainable thereby

Publications (2)

Publication Number Publication Date
BR112017004746A2 true BR112017004746A2 (pt) 2017-12-05
BR112017004746B1 BR112017004746B1 (pt) 2021-04-06

Family

ID=51662289

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017004746-2A BR112017004746B1 (pt) 2014-09-12 2014-09-12 Métodos para preparação de virossomas adjuvados e para otimizar a proporção adjuvante/antígeno de uma vacina à base de virossoma, virossoma adjuvado, composição farmacêutica, e, composição imunogênica

Country Status (12)

Country Link
US (1) US10588963B2 (pt)
EP (1) EP3191123B1 (pt)
JP (1) JP6466571B2 (pt)
KR (1) KR102277013B1 (pt)
CN (1) CN107073105B (pt)
AU (1) AU2014406150B2 (pt)
BR (1) BR112017004746B1 (pt)
CA (1) CA2960948C (pt)
ES (1) ES2807607T3 (pt)
NZ (1) NZ730357A (pt)
RU (1) RU2694367C2 (pt)
WO (1) WO2016039619A1 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016039619A1 (en) 2014-09-12 2016-03-17 Bestewil Holding B.V. Methods for providing adjuvanted virosomes and adjuvanted virosomes obtainable thereby
CN106243230B (zh) * 2016-08-26 2020-01-17 北京岱瑞汛生物科技发展有限公司 一种具有霍乱弧菌毒素a亚基和金黄色葡萄球菌特点的人工蛋白及其应用
US11523988B2 (en) 2018-11-29 2022-12-13 Catalent U.K. Swindon Zydis Limited Oral dispersible vaccine comprising virosomes
CN110128543A (zh) * 2019-04-01 2019-08-16 上海交通大学 一种仿病毒囊泡及其制备方法以及其用途
US11278617B2 (en) 2020-03-31 2022-03-22 Engimata, Inc Immunogenic composition forming a SARS-CoV-2 vaccine, and a method for its manufacture
US11559577B2 (en) 2020-03-31 2023-01-24 Engimata, Inc. Immunogenic composition forming a vaccine, and a method for its manufacture
CN114989269B (zh) * 2022-06-30 2023-09-19 天康制药股份有限公司 一种牛赤羽免疫原性抗原及疫苗

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4542212A (en) 1975-10-14 1985-09-17 Institut Pasteur Phosphorylated 3-glyceryl-esters of glucose
AU655823B2 (en) 1991-05-08 1995-01-12 Crucell Switzerland Ag Immunostimulating and immunopotentiating reconstituted influenza virosomes and vaccines containing them
US5936076A (en) 1991-08-29 1999-08-10 Kirin Beer Kabushiki Kaisha αgalactosylceramide derivatives
GB0103170D0 (en) 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
US7592008B2 (en) * 2000-11-20 2009-09-22 The Board Of Trustees Of The University Of Illinois, A Body Corporate And Politic Of The State Of Illinois Membrane scaffold proteins
CN100488491C (zh) 2002-11-21 2009-05-20 派维翁生物技术有限公司 高效融合小泡,其制备方法和含有该小泡的药物组合物
EP1447080A1 (en) 2003-02-13 2004-08-18 Bestewil Holding B.V. Method for producing virosome-like particles
AR056245A1 (es) 2003-06-19 2007-10-03 Bestewil Holding Bv Membranas virales reconstituidas funcionales que contienen un coadyuvante
DE602005025342D1 (de) * 2004-05-28 2011-01-27 Glaxosmithkline Biolog Sa Impfstoffzusammensetzungen mit virosomen und einem saponin-adjuvans
EP1652914A1 (en) * 2004-10-27 2006-05-03 Berna Biotech AG Virosome particles comprising antigens from influenza virus and Hepatitis B virus
WO2007099387A1 (en) 2006-03-03 2007-09-07 Mymetics Corporation Virosome-like vesicles comprising gp41-derived antigens
CN102078606B (zh) * 2010-12-08 2014-12-31 中国人民解放军军事医学科学院微生物流行病研究所 一种呼吸道合胞病毒体疫苗及其制备方法
US9241988B2 (en) 2012-04-12 2016-01-26 Avanti Polar Lipids, Inc. Disaccharide synthetic lipid compounds and uses thereof
WO2016039619A1 (en) 2014-09-12 2016-03-17 Bestewil Holding B.V. Methods for providing adjuvanted virosomes and adjuvanted virosomes obtainable thereby

Also Published As

Publication number Publication date
KR20170063684A (ko) 2017-06-08
CA2960948A1 (en) 2016-03-17
CN107073105B (zh) 2021-04-06
EP3191123A1 (en) 2017-07-19
US20170189523A1 (en) 2017-07-06
KR102277013B1 (ko) 2021-07-14
CA2960948C (en) 2023-04-04
NZ730357A (en) 2021-12-24
AU2014406150A1 (en) 2017-03-30
ES2807607T3 (es) 2021-02-23
JP2017528484A (ja) 2017-09-28
AU2014406150B2 (en) 2020-09-10
BR112017004746B1 (pt) 2021-04-06
RU2017108644A3 (pt) 2018-10-12
RU2017108644A (ru) 2018-10-12
CN107073105A (zh) 2017-08-18
US10588963B2 (en) 2020-03-17
RU2694367C2 (ru) 2019-07-12
JP6466571B2 (ja) 2019-02-06
WO2016039619A1 (en) 2016-03-17
EP3191123B1 (en) 2020-06-03

Similar Documents

Publication Publication Date Title
BR112017004746A2 (pt) métodos para preparação de virossomas adjuvados, para otimizar a proporção adjuvante/antígeno de uma vacina à base de virossoma e para imunizar um indivíduo contra uma doença, virossoma adjuvado, composição farmacêutica, e, composição imunogênica.
MX2022006603A (es) Vacuna contra el virus de la influenza de amplio espectro.
CL2018001053A1 (es) Vacuna contra el virus sincicial respiratorio
NI201700128A (es) Composiciones de acido obeticolico y metodos de uso.
MX2017012220A (es) Composiciones adyuvantes y metodos relacionados.
BR112013022397A2 (pt) vacinas combinadas com doses menores de antígeno e/ou adjuvante
BR112016024644A2 (pt) vacinas de ácido nucleico
BR112018012873A2 (pt) vacina de vírus zika
CO6331297A2 (es) Composiciones adyuvantes novedosas
BR112013017382A2 (pt) métodos para preparação de glicoesfingolipídios e usos destes
BR112016028961A8 (pt) fibras eletrotorcidas, seu método de preparação e seu uso, bem como composição, e kit
AR067087A1 (es) Composicion de vacuna y metodo para elaborarla
BR112016029513A2 (pt) vacina; processo para a preparação de uma vacina; e método para vacinar um animal não humano
PE20151588A1 (es) Vacuna contra el virus del dengue
EA201490395A1 (ru) Способ получения фармацевтических композиций, содержащих финголимод
PH12017501370A1 (en) Bivalent swine influenza virus vaccine
CL2016001375A1 (es) Composición, que comprende agente bioactivo (inmunógeno) dispersado en gotitas de aceite, polímero de recubrimiento entérico, un polímero mucoadhesivo, su método de preparación y uso para la administración oral de un agente bioactivo.
CU20180025A7 (es) Proceso de preparación de una vacuna tetravalente atenuada contra el virus del dengue
AR088907A1 (es) Vacuna
BR112014031386A2 (pt) vacinas para meningococos do sorogrupo x
AR099960A1 (es) Procedimientos y composición farmaceutica para inducir una respuesta inmunitaria
ECSP18081582A (es) Constructos de alfavirus vivo atenuado y métodos y usos de los mismos
GT201000066A (es) Una vacuna multicomponente o monocomponente, para ser utilizada contra la enfermedad de chagas, composiciones farmaceuticas que las contienen, procedimiento para la obtención del inmunógeno de dichas vacunas y acido nucleico utilizado en dicho proced
MX2017006744A (es) Composiciones adyuvantes y metodos relacionados.
CO2023015036A2 (es) Composición inmunogénica contra la influenza

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B15K Others concerning applications: alteration of classification

Ipc: A61K 39/12 (2006.01), A61K 39/39 (2006.01), A61K 4

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B09W Correction of the decision to grant [chapter 9.1.4 patent gazette]

Free format text: REF. A RPI NO 2597 DE 13/10/2020.

B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 12/09/2014, OBSERVADAS AS CONDICOES LEGAIS.